RPID
Rapid Micro Biosystems, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.05
P/S
3.07
EV/EBITDA
-2.43
DCF Value
$-17.96
FCF Yield
-30.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
17.4%
Operating Margin
-141.1%
Net Margin
-140.3%
ROE
-95.4%
ROA
-63.0%
ROIC
-82.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $11.3M | $-12.5M | $-0.28 |
| FY 2025 | $33.6M | $-47.1M | $-1.05 |
| Q3 2025 | $7.8M | $-11.5M | $-0.25 |
| Q2 2025 | $7.3M | $-11.9M | $-0.27 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.60
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.